A Phase 1 Double-blind, Placebo-controlled, Randomized, Single- And Multiple-ascending Dose Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Pf-06293620 In Subjects With Type 2 Diabetes Mellitus

Trial Profile

A Phase 1 Double-blind, Placebo-controlled, Randomized, Single- And Multiple-ascending Dose Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Pf-06293620 In Subjects With Type 2 Diabetes Mellitus

Completed
Phase of Trial: Phase I

Latest Information Update: 12 May 2017

At a glance

  • Drugs PF 6293620 (Primary) ; PF 6293620 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; First in man
  • Sponsors Pfizer
  • Most Recent Events

    • 08 May 2017 Status changed from active, no longer recruiting to completed.
    • 08 Nov 2016 Status changed from recruiting to active, no longer recruiting.
    • 12 Oct 2016 Planned End Date changed from 1 Aug 2016 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top